-
2022-502043-35-00
5
Advanced Biliary Tract Cancers
-
2024-512754-16-00
5
Prostate cancer
-
2024-514244-81-00
5
Uncomplicated candidemia
-
2024-515362-13-00
10
Philadelphia-negative myeloproliferative neoplasms are frequent and ch
-
2024-517621-54-00
5
High-risk non-muscle invasive bladder cancer (NMIBC) after transurethr
-
2024-518139-12-00
4
locally advanced or metastatic Pancreatic ductal adenocarcinoma
-
2024-518199-30-00
9
Soft tissue sarcoma patients
-
2025-521317-50-00
5
Cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs)
-
2025-521322-14-00
4
Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation,
-
2025-523495-23-00
5
Resected Pancreatic Ductal Adenocarcinoma (PDAC)
-
2025-523630-59-00
9
colon carcinoma metastases
-
2025-523793-16-00
4
Homeostatic iron regulator gene-related hereditary hemochromatosis
-
2024-515181-14-00
5
2026-05-20
Patients with preoperative biliary stent treated by
pancreaticoduodene
-
2025-522093-36-00
10
2026-05-20
Cancer cachexia
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2024-514327-42-00
4
2025-12-18
Advanced neuroendocrine carcinomas (NECs) of the digestive system or u
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2023-508057-19-00
5
2025-09-23
Advanced HER2-expressing Biliary Tract Cancer
-
2024-516233-12-00
3
2025-08-08
Advanced pancreatic adenocarcinoma
-
2024-516525-31-01
5
2025-07-14
Primary Biliary Cholangitis
-
2024-514459-14-00
4
2025-04-22
Non-Small Cell Lung Cancer
-
2024-513317-12-00
5
2025-02-05
Pancreatic cancer
-
2024-519132-17-00
4
2025-01-29
NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer